Maria D F S Barbosa

Summary

Affiliation: Xencor Inc
Country: USA

Publications

  1. ncbi Regulated expression of the Escherichia coli lepB gene as a tool for cellular testing of antimicrobial compounds that inhibit signal peptidase I in vitro
    Maria D F S Barbosa
    Departments of Antimicrobial Research, Bristol Myers Squibb Company, Wilmington, Delaware 19880, USA
    Antimicrob Agents Chemother 46:3549-54. 2002
  2. ncbi Clinical link between MHC class II haplotype and interferon-beta (IFN-beta) immunogenicity
    Maria D F S Barbosa
    Xencor, Inc, 111 W Lemon Avenue, Monrovia, CA 91016, USA
    Clin Immunol 118:42-50. 2006
  3. ncbi A multitarget assay for inhibitors of membrane-associated steps of peptidoglycan biosynthesis
    Maria D F S Barbosa
    Department of Antimicrobial Research, Bristol Myers Squibb Pharmaceuticals, Wilmington, Delaware 19880, USA
    Anal Biochem 306:17-22. 2002
  4. ncbi An array of target-specific screening strains for antibacterial discovery
    Joseph A DeVito
    Department of Antimicrobial Research, Bristol Myers Squibb Company, Wilmington, DE 19880, USA
    Nat Biotechnol 20:478-83. 2002
  5. ncbi Development of a whole-cell assay for peptidoglycan biosynthesis inhibitors
    Maria D F S Barbosa
    Department of Antimicrobial Research, Bristol Myers Squibb Pharma, Wilmington, Delaware 19880, USA
    Antimicrob Agents Chemother 46:943-6. 2002

Detail Information

Publications5

  1. ncbi Regulated expression of the Escherichia coli lepB gene as a tool for cellular testing of antimicrobial compounds that inhibit signal peptidase I in vitro
    Maria D F S Barbosa
    Departments of Antimicrobial Research, Bristol Myers Squibb Company, Wilmington, Delaware 19880, USA
    Antimicrob Agents Chemother 46:3549-54. 2002
    ..MD3 and MD4, a reactive analog of MD3, inhibited growth of E. coli under-expressing lepB. However, growth rescue in the presence of these compounds following increased lepB expression was observed only after prolonged incubation...
  2. ncbi Clinical link between MHC class II haplotype and interferon-beta (IFN-beta) immunogenicity
    Maria D F S Barbosa
    Xencor, Inc, 111 W Lemon Avenue, Monrovia, CA 91016, USA
    Clin Immunol 118:42-50. 2006
    ..In addition, elucidation of the factors underlying the anti-IFN-beta antibody response should accelerate the engineering of less immunogenic IFN-beta therapeutics...
  3. ncbi A multitarget assay for inhibitors of membrane-associated steps of peptidoglycan biosynthesis
    Maria D F S Barbosa
    Department of Antimicrobial Research, Bristol Myers Squibb Pharmaceuticals, Wilmington, Delaware 19880, USA
    Anal Biochem 306:17-22. 2002
    ..Using a 96-well assay format, the IC50 values for vancomycin, tunicamycin, flavomycin, and bacitracin were 1.1 microM, 0.01 microg/ml, 0.03 microg/ml, and 0.7 microg/ml, respectively...
  4. ncbi An array of target-specific screening strains for antibacterial discovery
    Joseph A DeVito
    Department of Antimicrobial Research, Bristol Myers Squibb Company, Wilmington, DE 19880, USA
    Nat Biotechnol 20:478-83. 2002
    ..As an example of the target specificity of the approach, compounds identified in the whole-cell screen for MurA inhibitors were also found to block the biochemical function of the target when tested in vitro...
  5. ncbi Development of a whole-cell assay for peptidoglycan biosynthesis inhibitors
    Maria D F S Barbosa
    Department of Antimicrobial Research, Bristol Myers Squibb Pharma, Wilmington, Delaware 19880, USA
    Antimicrob Agents Chemother 46:943-6. 2002
    ..The pathway assay used in conjunction with assays for individual enzymes provides an efficient means of detecting and characterizing novel antimicrobial agents...